Drug Profile

MRG 006

Alternative Names: MRG-006; MRG-006A

Latest Information Update: 18 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Miracogen
Class Antineoplastics; Immunoconjugates
Mechanism of Action Glypican 3 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Liver cancer
No development reported Solid tumours

Most Recent Events

05 Apr 2024 Preclinical trials in Liver cancer in China (unspecified route) prior to April 2024
05 Apr 2024 Miracogen announces intention to submit an Investigational New Drug (IND) application to the US FDA and NMPA for liver cancer in 2024
05 Apr 2024 Pharmacokinetics, pharmacodynamics and adverse events data from a preclinical study in Liver cancer presented at the 115^th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com